Stock Research: Phathom Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Phathom Pharmaceuticals

NSQ:PHAT US71722W1071
34
  • Value
    52
  • Growth
    92
  • Safety
    Safety
    26
  • Combined
    60
  • Sentiment
    19
  • 360° View
    360° View
    34
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 34 (better than 34% compared with alternatives), overall professional sentiment and financial characteristics for the stock Phathom Pharmaceuticals are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Phathom Pharmaceuticals. The consolidated Value Rank has an attractive rank of 52, which means that the share price of Phathom Pharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 52% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 92, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 19. Professional investors are more confident in 81% other stocks. Worryingly, the company has risky financing, with a Safety rank of 26. This means 74% of comparable companies have a safer financing structure than Phathom Pharmaceuticals. ...read more

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
52 n/a n/a n/a
Growth
92 n/a n/a n/a
Safety
Safety
26 n/a n/a n/a
Sentiment
19 n/a n/a n/a
360° View
360° View
34 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
46 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
15 n/a n/a n/a
Sentiment
19 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
52 n/a n/a n/a
Growth
92 n/a n/a n/a
Safety Safety
26 n/a n/a n/a
Combined
60 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
73 n/a n/a n/a
Price vs. Earnings (P/E)
1 n/a n/a n/a
Price vs. Book (P/B)
84 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
52 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
87 n/a n/a n/a
Profit Growth
56 n/a n/a n/a
Capital Growth
66 n/a n/a n/a
Stock Returns
66 n/a n/a n/a
Growth
92 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
3 n/a n/a n/a
Refinancing
51 n/a n/a n/a
Liquidity
51 n/a n/a n/a
Safety Safety
26 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Phathom Pharmaceuticals and broaden your portfolio horizons.

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

FedEx

NYQ:FDX
Country: USA
Industry: Air Freight & Logistics
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: